Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis

Oncogene

Volumn 33, Issue 21, 2014, Pages 2807-2813

  Rodriguez Paredes, M ^a   Martinez De Paz, A ^a   Simo Riudalbas L ^a   Sayols, S ^a   Moutinho, C ^a   Moran, S ^a   Villanueva, A ^g   Vazquez Cedeira M ^b   Lazo, P A ^c,d   Carneiro, F ^c,d   Moura, C S ^e   Vieira, J ^f   Teixeira, M R ^f   Esteller, M ^a,g,h  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^e University of Porto   (Portugal)

^f PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^g UNIVERSITY OF BARCELONA   (Spain)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

chemotherapy; gene amplification; histone methyltransferase; lung cancer; overexpression; SETDB1

Indexed keywords

HISTONE METHYLTRANSFERASE; MESSENGER RNA; MITHRAMYCIN; SETDB1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TRANSFORMED CELL; TUMOR INVASION;

MUS MUSCULUS;

ADENOCARCINOMA; ANIMALS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTEIN METHYLTRANSFERASES;

EID: 84901508481     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.239     Document Type: Article

References (49)

1. Jones PA Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692. (Pubitemid 46273572)
2. Berdasco M Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010; 19: 698-711.
3. Fu ̈ llgrabe J Kavanagh E Joseph B Histone onco-modifications. Oncogene 2011 30 3391-3403.
4. Fraga MF Ballestar E Villar-Garea A Boix-Chornet M Espada J Schotta G et al. Loss of acetylation at Lys16 and trimethylation at Lys20of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
5. Seligson DB Horvath S Shi T Yu H Tze S Grunstein M et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435 : 1262-1266. (Pubitemid 40943093)
6. Schneider R Bannister AJ Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci 2002; 27: 396-402. (Pubitemid 34874749)
7. Esteller M . Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006; 94: 179-183. (Pubitemid 43151531)
8. Yoshimi A Kurokawa M. Key roles of histone methyltransferase and demethylase in leukemogenesis. J Cell Biochem 2011; 112: 415-424.
9. Rodŕguez-Paredes M Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-339.
10. Chen H Tu SW Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280: 22437-22444. (Pubitemid 40827899)
11. Yu J Cao Q Mehra R Laxman B Yu J Tomlins SA et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12: 419-431. (Pubitemid 350046407)
12. Beke L Nuytten M Van Eynde A Beullens M Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007; 26: 4590-4595. (Pubitemid 47037047)
13. Taniguchi H Jacinto FV Villanueva A Fernandez AF Yamamoto H Carmona FJ et al. Silencing of kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene 2012; 31: 1988-1994.
14. Varambally S Dhanasekaran SM Zhou M Barrette TR Kumar-Sinha C Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 4 19: 624-629.
15. Bracken AP Pasini D Capra M Prosperini E Colli E Helin K. EZH2 is downstream of the pRB-E2F pathway essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-5335. (Pubitemid 37279943)
16. Kleer CG Cao Q Varambally S Shen R Ota I Tomlins SA et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611. (Pubitemid 37205983)
17. Yap DB Chu J Berg T Schapira M Cheng SW Moradian A et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively a ltered PRC2 catalytic activity to increase H3K27 trimethylation. Blood 2011; 117: 2451-2459.
18. Canaani E Nakamura T Rozovskaia T Smith ST Mori T Croce CM et al. ALL-1/MLL1 a homologue of Drosophila TRITHORAX modifies chromatin and is directly involved in infant acute leukaemia. Br J Cancer 2004; 90: 756-760. (Pubitemid 38406582)
19. Okada Y Feng Q Lin Y Jiang Q Li Y Coffield VM et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121: 167-178. (Pubitemid 40546386)
20. Berdasco M Ropero S Setien F Fraga MF Lapunzina P Losson R et al. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Na tl Acad Sci USA 2009; 106: 21830-21835.
21. Ceol CJ Houvras Y Jane-Valbuena J Bilodeau S Orlando DA Battisti V et al. The histone methyltransferase SETDB1 is recurrently amplified in m elanoma and accelerates its onset. Nature 2011; 471: 513-517.
22. Macgregor S Montgomery GW Liu JZ Zhao ZZ Henders AK Stark M et al. Genome-wide association study identifies a ne w melanoma susceptibility locus at 1q21.3. Nat Genet 2011; 43: 1114-1118.
23. Schultz DC Ayyanathan K Negorev D Maul GG Rauscher 3rd FJ. SETDB1: a novel KAP-1-associated histone H3 lysin e 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev 2002; 16: 919-932. (Pubitemid 34408542)
24. Yang L Xia L Wu DY Wang H Chansky H A Schubach WH et al. Molecular cloning of ESET a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene 2002; 21: 148-152. (Pubitemid 34076387)
25. Li H Rauch T Chen ZX SzabóPE Riggs AD Pfeifer GP The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells J Biol Chem 2006 281 19489-19500. (Pubitemid 44035453)
26. Matsui T Leung D Miyashita H Maksakova IA Miyachi H Kimura H et al. Proviral silencing in embryonic stem cells requires the histone methyltransferase ESET. Nature 2010; 464: 927-931.
27. Bilodeau S Kagey MH Frampton GM Rahl PB Young RA. SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state. Genes Dev 2009; 23: 2484-2489.
28. Karimi MM Goyal P Maksakova IA Bilenky M Leung D Tang JX et al. DNA methylation and SETDB1/H3K9me3 regulate predominantly distinct sets of genes retroelements and chimeric transc ripts in mESCs. Cell Stem Cell 2011; 8: 676-687.
29. Cho S Park JS Kang YK. Dual functions of histone-lysine N-methyltransferase Setdb1 protein at promyelocytic leukemia-nuclear body (PML-NB): main taining PML-NB structure and regulating the expression of its associated genes. J Biol Chem 2011; 286: 41115-41124.
30. Watanabe H Soejima K Yasuda H Kawada I Nakachi I Yoda S et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 2008; 8: 15.
31. Albertson DG. Gene amplification in cancer. Trends Genet 2006; 22: 447-455. (Pubitemid 44093770)
32. Arteaga CL Sliwkowski MX Osborne CK Perez EA Puglisi F Gianni L. Treatment o f HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011; 9: 16-32.
33. Barretina J Caponigro G Stansky N Venkatesan K Margolin AA Kim S et al. The cancer cell line encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
34. Sun P Xia S Lal B Eberhart CG Quinones-Hinojosa A Maciaczy k J et al. DNER an epigenetically modulated gene regulates glioblastoma-derived neurosphere cell differenciation and tumor propagation. Stem Cells 2009; 27: 1473-1486.
35. Wajapeyee N Serra RW Zhu X Mahalingam M Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132: 363-374. (Pubitemid 351191995)
36. Daigle SR Olhava EJ The rkelsen CA Majer CR Sneeringer CJ Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53-65.
37. Zuber J Shi J Wang E Rappaport AR Herrmann H Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
38. Delmore JE Issa GC Lemieux ME Rahl PB Shi J Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
39. Dawso n MA Prinjha RK Dittmann A Giotopoulos G Bantscheff M Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529-533.
40. Ryu H Lee J Hagerty SW Soh BY McAlpin SE Cormier KA et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci USA 2006; 103: 19176-19181. (Pubitemid 350002846)
41. Jones Jr. DE Cui DM Miller DM. Expression of beta-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin. Oncogene 1995; 10: 2323-233 0.
42. Balsara BR Sonoda G du Manoir S Siegfried JM Gabrielson E Testa JR. Comparative genomic hybridization analysis detects frequent often high-level overrepresentation of DNA sequences at 3q 5p 7p and 8q in human non-small cell lung carcinomas. Cancer Res 1997; 57: 2116-2120. (Pubitemid 27247023)
43. Luk C Tsao MS Bayani J Shepherd F Squire JA. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectra l karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001; 125: 87-99. (Pubitemid 32448052)
44. Yakut T Schulten HJ Demir A Frank D Danner B Egeli U et al. Assessment of molecul ar events in squamous and non-squamous cell lung carcinoma. Lung Cancer 2006; 54: 293-301. (Pubitemid 44634136)
45. Goeze A Schlü ns K Wolf G Thäsler Z Petersen S Petersen I. Chromosomal imbalances of primary and metastasic lung adenocarcinomas. J Pathol 2002; 196: 8-16.
46. Sy SM Wong N Lee TW Tse G Mok TS Fan B et al. Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung Eur J Cancer 2004 40 1082-1094. (Pubitemid 38496267)
47. Hayashi M Kawauchi S Ueda K Kaneda Y Oga A Furuya T et al. Genomic alterations detected by comparative genomic hybridization in primary lung adenocarcinomas with special reference to the relationship with DNA ploidy. Oncol Rep 2005; 14: 1429-1435.
48. Cancer Genome Atlas Research Network. Comprenhensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
49. Wilkerson MD Yin X Walter V Zhao N Cab anski CR Hayward MC et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations copy number chromosomal instability and methylation. PLoS One 2012; 7: e36530.